Anticancer activity of ruthenium and osmium cyclometalated compounds: identification of ABCB1 and EGFR as resistance mechanisms

201940 citationsJournal Article

Authors

Switching from ruthenium to osmium reduces sensitivity towards ABCB1 resistance for cyclometalated anticancer drugs.

Good health and well-being

Published in: Inorganic Chemistry Frontiers

Volume 7, Issue 3, pp. 678-688

Field-Weighted Citation Impact: 2.83